What Clinicians Need to Know about Dengue in the United States

Overview

Dengue virus is endemic in several U.S. territories and freely associated states and has caused increasing numbers of travel-associated and locally acquired dengue cases in U.S. states in recent years. No preventative medicines or specific antiviral treatments are available for dengue. Severe dengue is a medical emergency—recognition of warning signs and appropriate clinical management are critical for reducing severe outcomes. During this COCA Call, presenters will discuss current dengue epidemiology in the United States and review dengue clinical features, current diagnostic testing recommendations, and clinical management guidelines.

Webinar

Presenters

Laura Adams, DVM, MPH, DACVPM
Epidemiologist
Dengue Branch, Division of Vector-Borne Diseases
National Center for Emerging and Zoonotic Infectious Diseases
Centers for Disease Control and Prevention

Liliana Sánchez-González, MD, MPH, CTropMed
Medical Epidemiologist
Dengue Branch, Division of Vector-Borne Diseases
National Center for Emerging and Zoonotic Infectious Diseases
Centers for Disease Control and Prevention

Call Objectives

COCA Call Objectives

At the conclusion of the session, the participant will be able to accomplish the following:

1. Cite background information on the topic covered during the presentation.
2. Identify CDC's role in the topic covered during the presentation.
3. Describe the topic's implications for clinicians.
4. Identify concerns and issues related to preparedness for and response to urgent public health threats.
5. Identify how an interprofessional team of healthcare providers can work with patients to promote disease prevention.

Activity-specific Objectives

At the conclusion of this session, the participant will be able to accomplish the following:

1. Summarize dengue epidemiology and transmission in the United States.
2. List the clinical features of dengue.
3. Explain dengue diagnostic testing for patients with suspected dengue.
4. Describe appropriate treatment for dengue patients according to severity classification.

Additional Resources

• Dengue
• Dengue Training Resources
• Dengue Clinical Management Pocket Guide
• Dengue Communication Resources

Continuing Education

Instructions for Obtaining Continuing Education (CE)

To receive continuing education (CE) for WC5003-102226—What Clinicians Need to Know about Dengue in the United States, please visit CDC TRAIN and search for the course in the Course Catalog using WC5003-102226. Follow the steps below by November 23, 2026. The registration code is COCA10222026.

To receive continuing education (CE) for WD5003-102226—What Clinicians Need to Know about Dengue in the United States, please visit CDC TRAIN and search for the course in the Course Catalog using WD5003-102226. Follow the steps below between November 24, 2026, and November 24, 2028.

1. Register for and complete the course.
2. Pass the post-assessment at 75%.
3. Complete the evaluation.
4. Visit Your Learning to access your certificates and transcript.

Accreditation Statements

In support of improving patient care, The Centers for Disease Control and Prevention is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

CME: The Centers for Disease Control and Prevention designates this live activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA CME: Credit Designation Statement – LiveThe Centers for Disease Control and Prevention has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits.

CNE: The Centers for Disease Control and Prevention designates this activity for 1 nursing contact hours.

CPE: The Centers for Disease Control and Prevention designated this Knowledge-based event for pharmacists to receive 0.1 CEUs in pharmacy education. The Universal Activity Number is JA4008229-0000-26-090-L04-P and enduring JA4008229-0000-26-091-H04-P.

CEU: The Centers for Disease Control and Prevention is authorized by IACET to offer 0.1 CEU's for this program.

CECH: Sponsored by the Centers for Disease Control and Prevention, a designated provider of continuing education contact hours (CECH) in health education by the National Commission for Health Education Credentialing, Inc. This program is designated for Certified Health Education Specialists (CHES^®) and/or Master Certified Health Education Specialists (MCHES^®) to receive up to 1 total Category I continuing education contact hours. Maximum advanced level continuing education contact hours available are 1. Continuing Competency credits available are 1. CDC provider number 98614.

AAVSB/RACE: This program was reviewed and approved by AAVSB RACE program for 1 hours of continuing education. Participants should be aware that some boards have limitations on the number of hours accepted in certain categories and/or restrictions on certain methods of delivery of continuing education. Please contact the AAVSB RACE program if you have any comments/concerns regarding this program's validity or relevancy to the veterinary profession.

For Certified Public Health Professionals (CPH): The Centers for Disease Control and Prevention is a pre-approved provider of Certified in Public Health (CPH) recertification credits and is authorized to offer 1 CPH recertification credits for this program.

DISCLOSURE: In compliance with continuing education requirements, all planners and presenters/moderators must disclose all financial relationships, in any amount, with ineligible companies over the previous 24 months as well as any use of unlabeled product(s) or products under investigational use.

CDC, our planners, and presenters/moderators wish to disclose they have no financial relationship(s) with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

Content will not include any discussion of the unlabeled use of a product or a product under investigational use.

CDC did not accept financial or in-kind support from ineligible companies for this continuing education activity.

CDC complies with applicable Federal civil rights laws and does not discriminate based on race, color, national origin, age, disability, religion, or sex. To learn more visit: https://www.hhs.gov/civil-rights/for-individuals/nondiscrimination/index.html.

Target Audience

• Physicians
• Nurses
• Pharmacists
• Veterinarians
• Physician Assistants
• Health Educators
• Other Clinicians

Additional Information

• Contact Information: coca@cdc.gov
• Support/Funding: Centers for Disease Control and Prevention, Office of Emergency Risk Communication
• Method of Participation: You may participate in the educational activity by viewing the program information above.